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Background: The purpose of this study was to quantify the risk of late
recurrence in patients with stage IA non-small cell lung cancer
(NSCLC) who remained recurrence-free for more than 5 years after
resection.
Methods: Between August 1992 and December 2002, a total of 519
patients with stage IA NSCLC underwent complete resection at our
institution. Recurrence-free probability was measured from the
benchmark of 5 years after primary tumor resection to the date of
first recurrence or last follow-up using the Kaplan-Meier method.
Results: Of a total of 519 patients, 434 remained recurrence-free for 5
years. Among these, 21 (4.8%) developed late recurrence more than 5
years after resection. Recurrence-free interval ranged from 1 to 53
months, and the median recurrence-free interval was 14 months from
the benchmark of 5 years after primary tumor resection. The 5-year
recurrence-free probability from the benchmark was 93%. Multivariate
Cox analysis demonstrated that vascular invasion significantly influ-
enced late recurrence (p  0.038). The 5-year recurrence-free proba-
bility from the benchmark was 84% for patients with vascular invasion
and 95% for patients without vascular invasion (p  0.001).
Conclusions: Patients with stage IA NSCLC with vascular invasion
harbor a significant risk of late recurrence more than 5 years after
complete resection. In patients with stage IA NSCLC with vascular
invasion, 5 years without recurrence is not sufficient to conclude that
NSCLC is cured. In contrast, patients without vascular invasion may be
declared to be cured at 5 years after resection if they are recurrence-free.
Key Words: Non-small cell lung cancer, Late recurrence, Stage IA,
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(J Thorac Oncol. 2010;5: 1246–1250)
In Japan, the recent increase in the frequency of detectingstage IA non-small cell lung cancer (NSCLC) can be
attributed to a nationwide mass screening system.1 For these
early-stage NSCLC patients, complete surgical resection pro-
vides the best possibility of cure.
The reported 5-year survival rates of patients with
resected stage IA NSCLC ranged from 80 to 93%.2–6 Al-
though many researchers have studied postoperative recur-
rence and its risk factors in patients with stage IA NSCLC
within the first 5 years after resection,1 information about the
survival of such patients beyond 5 years is limited.4,7
This study reviewed a large series of consecutive pa-
tients with stage IA NSCLC who had been operated on in a
single institution. Because of its long follow-up period, this
study was able to focus on long-term outcome and late
recurrence. The purposes of this study were to quantify the
risk of late recurrence in patients with stage IA NSCLC who
survived more than 5 years after resection and to suggest
long-term follow-up strategy.
PATIENTS AND METHODS
A total of 541 patients with pathologic stage IA
NSCLC, who underwent complete resection between August
1992 and December 2002, were identified in our departmen-
tal database. Complete resection was defined as cancer-free
surgical margins both grossly and histologically. Twenty-two
patients were excluded because of (1) preoperative chemo-
therapy or radiation therapy, or both (n  6), and (2) low-
grade pulmonary malignancies including carcinoid tumor,
mucoepidermoid carcinoma, or adenoid cystic carcinoma
(n 16). The remaining 519 patients were the study subjects.
Pathologic Evaluations
Histologic type was determined according to the World
Health Organization classification,8 and histologic grade was
diagnosed and categorized into well, moderately, and poorly
differentiated carcinomas according to the degree of structural
and cytologic atypia. Differentiation in squamous cell carcinoma
was determined based on degree of keratinization, intercellular
bridges, and squamous pearl formation. Poor differentiation in
adenocarcinoma was defined as a solid pattern tumor without
any clear gland formation. Blood and lymphatic vessels were
identified by hematoxylin-eosin, elastin (Victoria blue-van Gie-
son), and D2-40 immunohistochemical stainings. Vascular in-
vasion and lymphatic permeation were histologically diagnosed
by identifying cancer cells within blood and lymphatic vessels,
respectively. Disease stages were based on the tumor, node,
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metastasis classification of the International Union Against Can-
cer, 7th edition.9
Patient Follow-Up
We examined patients at 3-month intervals for the first 2
years and typically at 6-month intervals thereafter on an outpa-
tient basis. After 5 years from resection, we aimed at continuing
follow-up annually for at least 5 more years. The follow-up
evaluation included physical examination, chest radiography,
and blood examination including pertinent tumor markers.
Whenever any symptoms or signs of recurrence were detected,
further evaluations were performed, including computed tomog-
raphy scans of the chest and abdomen, brain magnetic resonance
imaging, and bone scintigraphy. Since 2004, integrated positron
emission tomography and computed tomography have also been
performed when appropriate.
We diagnosed recurrence based on compatible physical
examination and diagnostic imaging findings and confirmed
histologically when clinically feasible. The date of recurrence
was defined as the date of histologic proof or, in cases
diagnosed based upon clinicoradiological findings, the date of
identification by a physician.
In this study, we used the following criteria to define and
differentiate metachronous primary lung cancers based on the
modified criteria of Martini and Melamed10: tumors histologi-
cally different from the primary tumor and occurring at anatom-
ically separate sites or tumors histologically the same as the
primary tumor without systemic metastases or mediastinal
spread, developing after a tumor-free interval of at least 2 years.
We classified recurrence into two categories: (1) lo-
coregional disease was clinically or radiologically manifest in
the ipsilateral mediastinum, pleural cavity, supraclavicular
lymph nodes, or bronchial stump, and (2) distant disease was
located in the contralateral lung or outside the hemithorax of
the primary lesion.
Clinicopathologic Information
We reviewed the medical records of each patient for
clinicopathologic information including age (dichotomized at
the median age of 65 years), gender, smoking history (non-
smoker or ever-smoker), preoperative serum carcinoembry-
onic antigen level (cutoff at the normal upper limit of 5
ng/ml), extent of resection, maximum tumor dimension on
the resected specimen (2 cm or 2 cm), histology, histo-
logic differentiation (well differentiated or moderately/poorly
differentiated), lymphatic permeation (presence or absence),
and vascular invasion (presence or absence).
Statistical Analysis
The length of overall survival was defined as the
interval in months between the date of surgical resection and
the date of either death or the last follow-up. Recurrence-free
probability was calculated in months from the point of 5 years
after resection to the date of the first recurrence or last
follow-up. To calculate recurrence-free probability, patients
who died without recurrence or who were known to be
recurrence-free at the date of last contact were censored. For
univariate analyses, all cumulative survival rates were esti-
mated using the Kaplan-Meier method, and differences in
variables were evaluated using the log-rank test. Multivariate
analyses were performed using the Cox proportional hazards
regression model. Forward and backward stepwise proce-
dures were used to determine independent predictors. Annual
recurrence rates were determined by dividing the number of
recurrences in a certain year (r) by the sum of the number of
patients without recurrence for the entire year (p), the number
of recurrent patients in the year (r), and a half of the number
of patients without recurrence followed for less than the
entire year (c) according to the following formula:
Annual recurrence rate r/p r 0.5 c11–13
All p values reported were two sided, and the signifi-
cance level was set at less than 0.05. Analyses were per-
formed using the statistical software SPSS 11.0 (Dr. SPSS II
for Windows, standard version 11.0, SPSS Inc., Chicago, IL)
and GraphPad Prism (Prism for Windows, Version 5.02,
GraphPad Software, Inc., La Jolla, CA).
Data collection and analyses were approved, and the
need to obtain informed consent from each patient was
waived by the institutional review board in August 2009.
RESULTS
Table 1 shows the clinicopathologic characteristics of
519 patients with stage IA NSCLC. The overall survival rates
of the 519 patients with stage IA NSCLC at 5 and 10 years
after resection were 88.0% and 74.4%, respectively. By 5
years after resection, 35 had died of disease and 32 had died
of other causes. Eighteen were alive with disease. The re-
maining 434 patients were alive and recurrence-free for the
first 5 years. The median follow-up period of these 5-year
recurrence-free survivors was 44 months after the first 5 years
(range, 1–86 months). Among the 434 patients, 21 (4.8%)
developed recurrence. Recurrence was locoregional in 9 pa-
tients and distant in 12 patients (Table 2).
From the point of 5 years after primary tumor resection,
the recurrence-free intervals ranged from 1 to 53months, and the
median recurrence-free interval was 14 months for the 5-year
recurrence-free survivors. For these survivors, the recurrence-
free probability was 93.3% at 5 years after the first 5 years. Table
3 lists the recurrence-free probabilities at 5 years after the 5-year
benchmark date according to clinicopathologic features. On
univariate analysis, ever-smoker, nonadenocarcinoma histology,
poor/moderate histologic differentiation, and presence of vascu-
lar invasion were shown to be significant risk factors for late
recurrence beyond 5 years. Recurrence-free probability was not
statistically different between groups stratified by age, gender,
preoperative serum carcinoembryonic antigen level, extent of
resection, maximum tumor dimension on the resected specimen,
histology, or lymphatic permeation.
On multivariate analysis with the Cox regression
model, the presence of vascular invasion remained a statisti-
cally significant predictor for late recurrence more than 5
years after surgery (hazard ratio: 2.74, p  0.038; Table 4).
The recurrence-free probability at 5 years after the first 5
years for patients without vascular invasion was 95.2%,
whereas that for patients with vascular invasion was 83.7%
(p  0.001; Figure 1).
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The recurrence rate per year peaked in the second year
after resection and gradually decreased thereafter but contin-
ued at a rate of 0.5 to 2% beyond 5 years until 10 years after
resection (Figure 2). Figure 3 shows the recurrence rates per
year stratified by vascular invasion status. The recurrence rate
per year in patients without vascular invasion peaked in the
third year after resection but decreased thereafter, whereas
the recurrence rate per year in patients with vascular invasion
peaked in the second year after resection and continued at a
higher rate of 2 to 10% until 9 years from resection.
DISCUSSION
In patients with NSCLC, 5-year disease-free survival is
currently the benchmark of cure. However, there are two issues
with the follow-up of patient with NSCLC: When can cure be
declared with confidence? For how long should follow-up ex-
aminations be continued? To examine these questions, we quan-
tified the risk of late recurrence in patients with stage IA NSCLC
who survived without recurrence for more than 5 years after
resection. We were able to investigate long-term outcome in a
large series of patients with stage IANSCLC because of the long
follow-up period (the median follow-up period after resection of
5-year recurrence-free survivors was 104 months).
Recurrence in NSCLC is most frequent during the first
2 years after resection, and more than 80% of recurrence
occurs within this time.4,14 In the current study, the recurrence
rate per year in the entire cohort peaked in the second year
after resection and gradually decreased thereafter (Figure 2).
Okada et al.15 reported a 10-year survival rate of 91%
among 421 5-year survivors of stage I to IIIB NSCLC, and
Martini et al.16 reported a 10-year survival rate of 92.4%
among 686 5-year survivors of stage I to IIIA disease. Both
studies concluded that late recurrence beyond 5 years was
infrequent. They concluded that 5 years after resection is
sufficient to declare that an NSCLC patient is cured because
of the low recurrence incidence.
In this study involving only stage IA patients, the
number of patients studied was 519, and 434 of them were
recurrence-free at 5 years after resection. Recurrence devel-
oped in 4.8% of the 5-year recurrence-free survivors. Delayed
recurrence was locoregional in 2.1% and distant in 2.8% of
patients. These recurrence rates in patients with stage IA
NSCLC were lower than those of the previous studies, in-
cluding stage IB or higher patients.
Okada et al.15 reported that disease stage, nodal status,
gender, or histology did not affect long-term survival. By mul-
tivariate analyses, however, we identified one independently
significant predictor of late recurrence in stage IA 5-year recur-
rence-free survivors: the presence of vascular invasion (hazard
ratio: 2.74). The recurrence rate per year in patients without
vascular invasion peaked at a rate of 2% in the third year after
resection and gradually decreased thereafter. Although the re-
currence rates per year in these patients did not reach zero until
the 10th year after resection, they were less than 2% beyond 3
years after resection. In patients with vascular invasion, the
TABLE 1. Clinicopathologic Characteristics of 519 Patients
with Stage IA NSCLC
Characteristic No. of Patients (%)
Overall number 519
Age (yr)
65 258 (49.7)
65 261 (50.3)
Gender
Female 244 (47.0)
Male 275 (53.0)
Smoking habits
Nonsmoker 236 (45.5)
Ever-smoker 283 (54.5)
CEA
Within normal range 385 (74.2)
Elevated 132 (25.4)
Not measured 2
Extent of resection
Lobectomy 467 (90.0)
Segmentectomy or wedge resection 51 (9.8)
Pneumonectomy 1
Tumor size (mm)
20 217 (41.8)
20 302 (58.2)
Histologic type
Adenocarcinoma 416 (80.2)
Squamous cell carcinoma 80 (15.4)
Large cell carcinoma 14 (2.7)
Adenosquamous carcinoma 9 (1.7)
Histological differentiation
Well differentiated 288 (55.5)
Moderately/poorly differentiated 231 (44.5)
Lymphatic permeation
Absent 431 (83.0)
Present 88 (17.0)
Vascular invasion
Absent 423 (81.5)
Present 96 (18.5)
Numbers in parentheses are percentages.
CEA, preoperative serum carcinoembryonic antigen level, normal upper limit at 5
ng/ml.
TABLE 2. Initial Site of Failure in 21 Patients with Late
Recurrence
Initial Site N
Distant metastasis 12
Multiple organ metastases 5
Single organ metastasis 7
Multiple lung metastases 2
Brain 2
Bone 1
Liver 1
Adrenal gland 1
Locoregional recurrence 9
Mediastinal lymph nodes 4
Pleural dissemination 2
Supraclavicular lymph nodes 2
Bronchial stump 1
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recurrence rates per year peaked in the second year after resec-
tion and continued at a higher rate of 2 to 10% beyond 5 years
until 9 years after resection (Figure 3). The recurrence-free
probability after the first 5 years for patients with vascular
invasion was significantly higher than that for patients without
vascular invasion (p  0.001). These findings indicate that in
patients with stage IA NSCLC without vascular invasion, 5
years may be sufficient to declare that the patients are cured. In
contrast, patients with stage IA NSCLC with vascular invasion
need follow-up until at least 9 years after resection.
This study was retrospectively performed, and there was
limitation in the analysis. We only focused on late recurrence
risk beyond 5 years after resection and failed to analyze subse-
quent interventions and their outcomes after recurrent NSCLC
diagnosis. The current study shows that cancer recurrence still
occurs after 5 years although at a lower annual rate than during
TABLE 3. Recurrence-Free Probability Beyond 5 yr After Complete Resection and Clinicopathologic Characteristics
Characteristic
No. of
Patients (%)
No. of
Recurrences (%)
Recurrence-Free Probabilities from
5-yr Benchmark at 5 yr (%)
Univariate
p Value
Overall number 434 21 (4.8) 93.3
Age (yr)
65 237 (54.6) 9 (3.8) 95.2
65 197 (45.4) 12 (6.1) 90.7 0.211
Gender
Female 222 (51.2) 7 (3.2) 95.4
Male 212 (48.8) 14 (6.6) 91.2 0.072
Smoking habits
Nonsmoker 217 (50.0) 5 (2.3) 97.3
Ever-smoker 217 (50.0) 16 (7.4) 88.8 0.009a
CEA
Within normal range 337 (77.6) 15 (4.5) 94.1
Elevated 95 (21.9) 6 (6.3) 90.1 0.299
Not measured 2 0
Extent of resection
Lobectomy or pneumonectomy 395 (91.0) 19 (4.8) 93.5
Segmentectomy or wedge resection 39 (9.0) 2 (5.1) 90.1 0.805
Tumor size (mm)
20 174 (40.1) 7 (4.0) 94.1
20 260 (59.9) 14 (5.4) 92.9 0.400
Histologic type
Nonsquamous cell carcinoma 376 (86.6) 14 (3.7) 95.1
Squamous cell carcinoma 58 (13.4) 7 (12.1) 81.1 0.006a
Histological differentiation
Well differentiated 263 (60.6) 8 (3.4) 96.0
Moderately/poorly differentiated 171 (39.4) 13 (8.2) 88.2 0.009a
Lymphatic permeation
Absent 372 (85.7) 16 (3.0) 93.8
Present 62 (14.3) 5 (8.1) 90.1 0.197
Vascular invasion
Absent 369 (85.0) 12 (3.3) 95.2
Present 65 (15.0) 9 (13.8) 83.7 0.006a
aIndicates significance.
CEA, preoperative serum carcinoembryonic antigen level, normal upper limit at 5 ng/ml.
TABLE 4. Multivariate Analysis of Risk Factors for Late Recurrence Beyond 5 yr
Factors Unfavorable Favorable Hazard Ratio 95% CI p
Smoking habits Ever-smoker Nonsmoker 2.166 0.689–6.815 0.186
Histologic type Squamous cell carcinoma Nonsquamous cell carcinoma 1.612 0.567–4.584 0.370
Histological differentiation Moderately/poorly differentiated Well differentiated 1.318 0.436–3.982 0.625
Vascular invasion Present Absent 2.742 1.058–7.108 0.038a
aIndicates significance.
CEA, preoperative serum carcinoembryonic antigen level, normal upper limit at 5 ng/ml; CI, confidence interval.
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the first 5 years. This may justify further surveillance, but patient
benefit from identifying recurrence by annual follow-up beyond
5 years after resection was unclear.
In conclusion, 4.8% of patients with resected stage IA
NSCLC who remained recurrence-free for the first 5 years
later developed recurrence. In patients with stage IA NSCLC
with vascular invasion, 5 years without recurrence is not
sufficient to conclude that NSCLC is cured. In contrast,
patients without vascular invasion may be declared to be
cured at 5 years after resection if they are recurrence-free.
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FIGURE 1. Recurrence-free probability curves from the
point of 5 years after resection according to intratumoral
vascular invasion.
FIGURE 2. Annual recurrence rates after resection in the
entire cohort.
FIGURE 3. Annual recurrence rates after resection accord-
ing to intratumoral vascular invasion.
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